Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 14, Issue 5, Pages 284-296
Publisher
Springer Nature
Online
2016-12-13
DOI
10.1038/nrclinonc.2016.191
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 881PDIMPLEMENTATION OF ROUTINE BRCA GENE TESTING OF OVARIAN CANCER (OC) PATIENTS AT ROYAL MARSDEN HOSPITAL
- (2017) A. George et al. ANNALS OF ONCOLOGY
- Phase I and IIa studies of simtuzumab alone and in combination with FOLFIRI in patients with advanced solid tumors.
- (2017) Patricia LoRusso et al. JOURNAL OF CLINICAL ONCOLOGY
- Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review
- (2016) Diana M. Eccles et al. ADVANCES IN THERAPY
- Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germlineBRCA1/2mutation: a multistudy analysis of response rates and safety
- (2016) U. A. Matulonis et al. ANNALS OF ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and aBRCAmutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
- (2016) Ursula A. Matulonis et al. CANCER
- Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
- (2016) Susan M. Domchek et al. GYNECOLOGIC ONCOLOGY
- New paradigms forBRCA1/BRCA2testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study
- (2016) Inga Plaskocinska et al. JOURNAL OF MEDICAL GENETICS
- Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
- (2016) Yi Du et al. NATURE MEDICINE
- Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations
- (2016) Michal Yalon et al. PLoS One
- Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients
- (2016) Angela George et al. Scientific Reports
- UK BRCA mutation testing in patients with ovarian cancer
- (2015) Angela George BRITISH JOURNAL OF CANCER
- A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
- (2015) R. Ceccaldi et al. CANCER RESEARCH
- SEOM clinical guidelines in Hereditary Breast and ovarian cancer
- (2015) G. Llort et al. Clinical & Translational Oncology
- Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
- (2015) S. Kummar et al. CLINICAL CANCER RESEARCH
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
- (2015) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- AGO Austria recommendations for genetic testing of patients with ovarian cancer
- (2015) Christian Marth et al. WIENER KLINISCHE WOCHENSCHRIFT
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†
- (2014) I. A. McNeish et al. ANNALS OF ONCOLOGY
- Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer
- (2014) Francisco J. Candido-dos-Reis et al. CLINICAL CANCER RESEARCH
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface
- (2013) A J Lee et al. BRITISH JOURNAL OF CANCER
- Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
- (2013) J. E. Ang et al. CLINICAL CANCER RESEARCH
- New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential
- (2013) S. Banerjee et al. CLINICAL CANCER RESEARCH
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
- (2013) Kathryn P. Pennington et al. CLINICAL CANCER RESEARCH
- Keeping it simple: Genetics referrals for all invasive serous ovarian cancers
- (2013) R. Demsky et al. GYNECOLOGIC ONCOLOGY
- Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predictingBRCA1/2mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium
- (2013) Christine Fischer et al. JOURNAL OF MEDICAL GENETICS
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of Resistance to PARP Inhibitors—Three and Counting
- (2013) Tito Fojo et al. Cancer Discovery
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- The Role of PARP-1 and PARP-2 Enzymes in Metabolic Regulation and Disease
- (2012) Péter Bai et al. Cell Metabolism
- GermlineRAD51Cmutations in ovarian cancer susceptibility
- (2012) F Coulet et al. CLINICAL GENETICS
- On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
- (2012) X. Luo et al. GENES & DEVELOPMENT
- Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing
- (2012) Barbara M. Norquist et al. GYNECOLOGIC ONCOLOGY
- Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers
- (2012) Susan J. Ramus et al. HUMAN MUTATION
- Family History and Women With Ovarian Cancer
- (2012) Anne Lanceley et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
- (2012) Kelly L. Bolton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- Germline RAD51C mutations confer susceptibility to ovarian cancer
- (2012) Chey Loveday et al. NATURE GENETICS
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival
- (2012) Joyce Liu et al. Cancer Genetics
- A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer
- (2011) Sarah F. Adams et al. GYNECOLOGIC ONCOLOGY
- Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
- (2011) Shiyu Zhang et al. GYNECOLOGIC ONCOLOGY
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
- (2011) Da Yang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Germline mutations in RAD51D confer susceptibility to ovarian cancer
- (2011) Chey Loveday et al. NATURE GENETICS
- Mutations in BRIP1 confer high risk of ovarian cancer
- (2011) Thorunn Rafnar et al. NATURE GENETICS
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRCA in breast cancer: ESMO Clinical Practice Guidelines
- (2010) J. Balmana et al. ANNALS OF ONCOLOGY
- Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype
- (2010) Charlie Gourley et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
- (2010) Bryan T.J. Hennessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
- (2010) Raga Krishnakumar et al. MOLECULAR CELL
- Making the best of PARP inhibitors in ovarian cancer
- (2010) Susana Banerjee et al. Nature Reviews Clinical Oncology
- Evaluating Women With Ovarian Cancer for BRCA1 and BRCA2 Mutations
- (2010) Larissa A. Meyer et al. OBSTETRICS AND GYNECOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
- (2008) Joshua Z Press et al. BMC CANCER
- BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark
- (2008) M. Soegaard et al. CLINICAL CANCER RESEARCH
- Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study
- (2008) Kelly A. Metcalfe et al. GYNECOLOGIC ONCOLOGY
- The role of poly(ADP-ribosyl)ation in epigenetic events
- (2008) Delphine Quénet et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations
- (2008) David S.P. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- Effect ofBRCA1/2Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer
- (2007) Angela Chetrit et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started